Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
(2013) Inflammatory Bowel Diseases — Vol. 19, n° 10, p. 2111-2117 (2013)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse.
- Affiliations
Citations
De Vos, M., Louis, E. J., Jahnsen, J., Vandervoort, J. G. P., Noman, M., Dewit, O., Dʼhaens, G. R., Franchimont, D., Baert, F. J., Torp, R. A., Henriksen, M., Potvin, P. M. R., Van Hootegem, P. P., Hindryckx, P. M., Moreels, T. G., Collard, A., Karlsen, L. N., Kittang, E., Lambrecht, G., et al. (2013). Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflammatory Bowel Diseases, 19(10), 2111-2117. https://doi.org/10.1097/MIB.0b013e31829b2a37 (Original work published 2013)